Breo Ellipta Sales Below Estimates, Says Leerink Swann (THRX) (GSK)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
Theravance (THRX) Anoro COPD Studies Gives Baird Increased Confidence
March 14, 2014 10:32 AM EDTBaird analyst Brian Skorney has increased confidence in the potential of Theravance Inc. (NASDAQ: THRX) Anoro following randomized COPD studies. He reiterated an Outperform rating and price target of $44.00.
Skorney commented, "With positive results across three studies against either dose of fluticasone... More
